Hinge Health, Inc.
HealthcareNYSE:HNGE · New York Stock Exchange
+$0.59 today
Vol 1.01M · Avg 1.32M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-139.6%
avg -55.9%
ROIC
-141.3%
avg -59.4%
ROA
-70.9%
avg -30.0%
Analysis
ROA is currently the strongest return metric at -70.9% versus its period average of -30.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James Pursley | President | $523,993.00 | — | 46 | $435,400.00 | 0.56% |
Daniel A. Perez | Co-Founder, Chief Executive Officer & Director | $507,000.00 | — | 40 | $358,445.00 | 0.46% |
Gabriel Mecklenburg | Co-Founder, CTO & Executive Chairman | $500,000.00 | — | 37 | $530.00 | <0.01% |
James W. Budge | Chief Financial Officer | $444,652.00 | — | 59 | $435,400.00 | 0.56% |
Bianca Buck | Finance & Head of Investor Relations | — | — | — | — | — |
Jeffrey Krauss | Chief Medical Officer | — | — | — | — | — |
Milana Shapira | Chief of Staff to the CEO | — | — | — | — | — |
Alexander Annison | Chief Operating Officer | — | — | — | — | — |
David Wood | General Counsel | — | — | — | — | — |
Hassan Asghar | Chief Information Security Officer | — | — | — | — | — |
Erin Wilson | Senior Vice President of Sales & Strategy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
61
$95.77M
Net Sentiment
$95.77M
Net selling
Most Active
Budge James
17 transactions
1–10 of 61
Analysis
Insiders reported 0 buys worth $0.00 and 61 sells worth $95.77M over the last 12 months. That adds up to net selling of $95.77M. Budge James was the most active insider with 17 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +21.7% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +21.7% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Oscar Health, Inc.
NYSE:OSCR
$7.33B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.80B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.80B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
GeneDx Holdings Corp.
NASDAQ:WGS
$1.78B
Who manages HNGE?
Hinge Health, Inc. (HNGE) lists 11 active executives. The top listed executive is Bianca Buck, Finance & Head of Investor Relations.
Are HNGE insiders buying or selling?
Recent insider activity shows net selling of $100.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.